Bio-Techne Corp. - TECH STOCK NEWS

Bio-Techne Corporation (NASDAQ:TECH) reported strong financial results for Q2 FY2021, with organic revenue growth of 19% to $224.3 million and a 21% overall increase. GAAP EPS decreased to $1.15, mainly due to a prior year's non-recurring gain, but adjusted EPS rose by 50% to $1.62. Both the Protein Sciences and Diagnostics and Genomics segments saw record organic growth of 19%. The company also achieved an adjusted operating margin of 38.7%, up from 33.4% year-over-year, while paying down $125 million in debt.

Bio-Techne Corporation (NASDAQ: TECH) announced a quarterly dividend of $0.32 per share for the period ending December 31, 2020. This dividend will be payable on February 26, 2021, to shareholders on record as of February 12, 2021. Bio-Techne, a global life sciences firm, reported approximately $739 million in net sales for fiscal 2020, enhancing its appeal as an investment option. The Board will consider future dividends quarterly.

Bio-Techne Corporation (NASDAQ: TECH) has made a strategic minority investment in Changzhou Eminence Biotechnology Co., Ltd. This funding will help Eminence expand its GMP media production capacity and service capabilities in China. Eminence, founded in 2016, focuses on high-quality cell culture media crucial for biopharmaceutical manufacturing. The investment aims to leverage Bio-Techne's reputation and industry relationships to support the growing Chinese biopharmaceutical market. Both companies anticipate collaboration on GMP molecules for cell and gene therapies.

Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on February 2, 2021, at 8:00 a.m. CST to review its second quarter 2021 financial results. Interested parties can access the call via dial-in or through a webcast link. A recorded rebroadcast will be available from 11:00 a.m. CST on the same day until 11:00 p.m. CST on March 2, 2021. Bio-Techne specializes in high-quality purified proteins and reagents, generating approximately $739 million in net sales in fiscal 2020 with around 2,300 employees.

Bio-Techne Corporation (NASDAQ: TECH) announced that Chuck Kummeth, CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 2:00 p.m. EST. Access the live webcast on Bio-Techne's Investor Relations website. The company specializes in high-quality purified proteins and reagent solutions, generating approximately $739 million in net sales in fiscal 2020. With over 2,300 employees, Bio-Techne plays a vital role in research and diagnostics, offering products in protein analysis, genomic tools, and diagnostics.

Kantaro Biosciences, a joint venture with RenalytixAI (NASDAQ: RNLX), has received Emergency Use Authorization from the FDA for its COVID-SeroKlir antibody test kit. This semi-quantitative test detects IgG antibodies, demonstrating 98.8% sensitivity and 99.6% specificity. Manufactured in partnership with Bio-Techne Corporation (NASDAQ: TECH), production can reach up to 10 million tests monthly. The test aids in healthcare decision-making and assessing vaccine responses, underlining its importance in the ongoing fight against COVID-19.

Bio-Techne Corporation (NASDAQ: TECH) will be presenting at the Stephens Annual Investment Conference 2020 on November 17, 2020, at 3:00 p.m. EST. Chuck Kummeth, President and CEO, will lead the presentation, which will be available via a live webcast on the company's Investor Relations website.

In fiscal 2020, Bio-Techne generated approximately $739 million in net sales and employs over 2,300 people globally. The company specializes in developing high-quality proteins, diagnostic products, and genomic tools essential for scientific research and clinical diagnostics.

Bio-Techne Corporation (NASDAQ: TECH) has declared a quarterly dividend of $0.32 per share for the period ending September 30, 2020. This dividend is payable on November 27, 2020 to shareholders on record as of November 16, 2020. The company reported approximately $739 million in net sales for fiscal 2020 and employs over 2,300 people worldwide. Future dividends will be assessed quarterly by the Board of Directors.

Bio-Techne Corporation (NASDAQ:TECH) reported a robust first quarter for FY2021, ending September 30, with organic revenue growth of 10%, totaling $204.2 million. The GAAP EPS rose to $0.83 from $0.37 year-on-year, while adjusted EPS saw a 35% increase to $1.43. The Diagnostics and Genomics segment achieved 17% organic growth, bolstered by the launch of a new GMP manufacturing facility. Despite challenges from COVID-19, a positive long-term outlook is anticipated due to increased funding in life sciences.